Table 2.

IC₅₀ values (μM) against various agents in EGFR-mutant NSCLC cell lines

Cell Lines	EGFR-TKI	Chemotherapeutic agent	MET inhibitor		Protease inhibitor
	Afatinib	DOC	Crizotinib	Afatinib with Crizotinib (0.2 μM)	Bortezomib
HCC827	0.0019	0.0031	6.9	0.0018	0.0082
HCC827-AR1	>10†	>1†	7.9	4.8†	0.0094
HCC827-AR2	4.1†	0.0042	4.6	0.00019	0.0018
HCC827-ACR	>10†	>1†	N/A	6.3†	0.0084
HCC827-AR3	4.3†	0.0022	N/A	N/A	0.0068
HCC827-AR4	4.8†	0.003	N/A	N/A	0.0066
PC-9	0.0023	0.0022	N/A	N/A	0.014
PC-9-AR1	2†	0.0023	N/A	N/A	0.041
PC-9-AR2	2.2†	0.0056	N/A	N/A	0.0093
HCC4006	0.0031	0.0062	N/A	N/A	0.019
HCC4006-AR1	3.7†	0.062†	N/A	N/A	0.036
HCC4006-AR2	5.4†	0.0011	N/A	N/A	0.038
HCC4011	0.0052	0.0012	1.4	0.0041	0.001
HCC4011-AR1	3.3†	0.0018	1.5	7.1†	0.0042
HCC4011-AR2	4.1†	0.0019	1.8	4.4†	0.0049

DOC, docetaxel; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; N/A, not applicable.

^†The ratio of the IC₅₀ value in each resistant line to that in the parental line is higher than five-fold.